ENLV Enlivex Therapeutics

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
EN
01/10/2020

Underlying

ENLVEnlivex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enlivex Therapeutics

 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kr...

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset tra...

February 10, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteB...

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, expanding access to the token across a major global digital asset trading platform. WhiteBIT is the larg...

January 26, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initiated a process to voluntarily del...

January 23, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin...

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its treasury asset, the RAIN token, has been listed on the KuCoin cryptocurrency exchange effective January 6, 2026, expanding access to the token across a major global digital ass...

January 7, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAI...

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company’s plans following its recently closed $212,000,000 private placement. Mr. Novik will discuss the launch of Enlivex’s digital asset treasury strategy built around ...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch